Literature DB >> 21899912

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.

Takashi Nomiyama, Yuko Akehi, Hiromasa Takenoshita, Ryoko Nagaishi, Yuichi Terawaki, Hisahiro Nagasako, Tadachika Kudo, Takehiko Kodera, Kunihisa Kobayashi, Hidenori Urata, Toshihiko Yanase.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21899912     DOI： 10.1016/j.diabres.2011.08.016

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


× No keyword cloud information.
  35 in total

1.  Sitagliptin counteracts seasonal fluctuation of glycemic control.

Authors:  Tomohiro Matsuhashi; Motoaki Sano; Keiichi Fukuda; Shun Kohsaka; Yoshihiko Suzuki
Journal:  World J Diabetes       Date:  2012-06-15

2.  Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study.

Authors:  Tsuyoshi Nozue; Kazuki Fukui; Yutaka Koyama; Hiroyuki Fujii; Tomoyuki Kunishima; Hiroyuki Hikita; Kiyoshi Hibi; Akiyoshi Miyazawa; Ichiro Michishita
Journal:  Heart Vessels       Date:  2015-03-21       Impact factor: 2.037

3.  Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin.

Authors:  Rui Ma; Xiao-Long Deng; Qi-Qi-Ge Aleteng; Lei Li; Jun Zhu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-09       Impact factor: 3.249

4.  Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.

Authors:  Miyako Kishimoto; Mitsuhiko Noda
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

5.  Sitagliptin: Is It Effective in Routine Clinical Practice?

Authors:  Rita Mohan Dallumal; Siew Siang Chua; David Bin-Chia Wu; Shireene Ratna Vethakkan
Journal:  Int J Endocrinol       Date:  2015-05-18       Impact factor: 3.257

6.  Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.

Authors:  Yuichi Terawaki; Takashi Nomiyama; Hiroyuki Takahashi; Yoko Tsutsumi; Kunitaka Murase; Ryoko Nagaishi; Makito Tanabe; Tadachika Kudo; Kunihisa Kobayashi; Tetsuhiko Yasuno; Hitoshi Nakashima; Toshihiko Yanase
Journal:  Diabetol Metab Syndr       Date:  2015-05-17       Impact factor: 3.320

7.  Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).

Authors:  Yuichi Terawaki; Chikayo Iwaya; Takashi Nomiyama; Dai Shimono; Tsuyoshi Horikawa; Yuki Fujimura-Tanaka; Toru Shigeoka; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase; Daiji Kawanami
Journal:  Diabetol Int       Date:  2020-02-14

8.  Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.

Authors:  Tae Jung Oh; Hye Seung Jung; Jae Hyun Bae; Yeong Gi Kim; Kyeong Seon Park; Young Min Cho; Kyong Soo Park; Seong Yeon Kim
Journal:  J Korean Med Sci       Date:  2013-06-03       Impact factor: 2.153

9.  The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.

Authors:  Yuichi Terawaki; Takashi Nomiyama; Yuko Akehi; Hiromasa Takenoshita; Ryoko Nagaishi; Yoko Tsutsumi; Kunitaka Murase; Hisahiro Nagasako; Nobuya Hamanoue; Kaoru Sugimoto; Ayako Takada; Kenji Ito; Yasuhiro Abe; Yoshie Sasatomi; Satoru Ogahara; Hitoshi Nakashima; Takao Saito; Toshihiko Yanase
Journal:  Diabetol Metab Syndr       Date:  2013-02-28       Impact factor: 3.320

10.  Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.

Authors:  Makito Tanabe; Takashi Nomiyama; Ryoko Motonaga; Kunitaka Murase; Toshihiko Yanase
Journal:  BMC Endocr Disord       Date:  2015-09-17       Impact factor: 2.763
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.